Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Total Current Assets : $8,823 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Chugai Pharmaceutical Co's total current assets for the quarter that ended in Mar. 2024 was $8,823 Mil.

Chugai Pharmaceutical Co Total Current Assets Historical Data

The historical data trend for Chugai Pharmaceutical Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Total Current Assets Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

6,413.14

8,043.78

9,344.06

9,906.53

9,490.29

Chugai Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															9,179.62	9,004.23	8,502.01	9,490.29	8,823.04

Chugai Pharmaceutical Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Chugai Pharmaceutical Co's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5132.479	+	2214.812	+	1899.411	+	243.587
	=	9,490

Chugai Pharmaceutical Co's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5103.278	+	1599.728	+	1846.78	+	273.257
	=	8,823

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Chugai Pharmaceutical Co (OTCPK:CHGCF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Chugai Pharmaceutical Co's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5103.278	-	1706.844	+	0.75 * 1599.728	+	0.5 * 1846.78
=	5,520

Chugai Pharmaceutical Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

CHGCY:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines

From GuruFocus

T. Rowe Price Japan Fund Comments on Chugai Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 06-19-2020

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020

T. Rowe Price Japan Fund Makes 4 New Buys in 3rd Quarter

By David Goodloe David Goodloe • 10-19-2016

Jean Hynes Adds to Chugai Pharmaceutical Stake

By Kyle Ferguson Kyle Ferguson • 08-22-2016

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

By PRNewswire PRNewswire • 03-02-2023

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020